Resistant hypertension is characterised by failure to achieve a blood pressure of less than 140/90 mm Hg while on maximum tolerated doses of three diff erent classes of antihypertensive drugs, including a diuretic appropriate for kidney function.
1 While often ascribed to medication non-adherence, 2 true resistant cases of hypertension are linked to non-adherence to lifestyle modifi cations to control blood pressure, including low sodium diet, reduced alcohol ingestion, and weight reduction. 3 Several pharmacological regimens to treat such patients have inconsistent outcomes. It has been posited that the sympathetic nervous system and excess sodium intake are the principal drivers of resistant hypertension. 4 Despite this, targeted therapies, based on both pharmacological approaches (ie, α-β blockers) and devices (ie, renal denervation), have generated disappointing results. 4 Other adjuvant therapies include aldosterone antagonists such as spironolactone. 5 These drugs have a plausible physiological basis because the prevalence of hyperaldosteronism is higher than previously appreciated and the phenomenon of aldosterone so-called escape exists after long-term renin-angiotensin system blockade. 6 Although spironolactone has proven Spironolactone for resistant hypertension-hard to resist?
safe abortion are restricted, girls who become pregnant outside marriage might believe that self-harm or suicide are their only alternatives. 11, 12 Related to the phenomenon of early pregnancy is child marriage, which aff ects around 40 000 girls under the age of 18 years every day. 13 Child brides are typically removed from their families, peers, and educational opportunities, and face higher rates of unintended pregnancy, domestic violence, and sexually transmitted infections than their unmarried peers. Although few studies have assessed the mental health eff ects of child marriage, one study in the USA found that child marriage was associated with high rates of long-term psychiatric disorders.
14 Donor funding structures and the manner in which global health is currently addressed do not support the type of cross-cutting and multidisciplinary research that is needed to truly understand and stem the scourge of suicide among adolescent girls. Funding must be made available to catalyse research, programmes, and policy dialogues addressing the many sided nature of the challenge, with a particular focus on the role that harmful gender norms might have. We need improved monitoring and documentation of suicides and suicide attempts, and greater innovation in promoting mental health among adolescents. And as we move toward a new global development agenda and a new global strategy on the health of women, children, and adolescents, we must address the full range of health needs for adolescent girls, a crucial and previously neglected population. superior to renal denervation in some treatment studies, head-to-head trials are lacking. 7, 8 In The Lancet, Bryan Williams and colleagues 9 report on the PATHWAY-2 study that investigates the eff ect of spironolactone versus placebo, and two other drugs, bisoprolol and doxazosin, in a randomised, double-blind, crossover trial to determine which drug produced the greatest reduction in blood pressure when added to a pre-existing three-drug regimen. The authors hypothesised that resistant hypertension, driven by sodium retention, would be best managed by adjuvant diuretic therapy-ie, spironolactone. To this end a surrogate for sodium status, plasma renin, was assessed in an attempt to predict those most responsive to spironolactone-based therapies.
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After confi rmation of the presence of systolic blood pressures in excess of 130 mm Hg at home and 140 mm Hg in the clinic, and exclusion of those patients with advanced kidney disease, 335 individuals were randomised to a sequence comprising spironolactone (fi nal dose 50 mg, n=285), bisoprolol (fi nal dose 10 mg, n=285), doxazosin (fi nal dose 8 mg, n=282), or placebo (n=274) for 12 weeks. After each treatment cycle, patients were treated sequentially with the remaining drugs, each for an additional 12-week period, with doses force-titrated (doubled) at 6 weeks. 230 patients received both doses of all treatments. The trial's primary endpoint was the diff erence in average home systolic blood pressure between spironolactone and placebo, followed if signifi cant by diff erences in home systolic blood pressure between spironolactone and the mean of the other two drugs, followed by the other two drugs individually.
In terms of diff erence in average home systolic blood pressure, spironolactone was superior to placebo (-8·70 mm Hg [95% CI -9·72 to -7·69]), to the mean of doxazosin and bisoprolol (-4·26 [-5·13 to -3·38]), and to doxazosin (-4·03 [-5·04 to -3·02]) and bisoprolol (-4·48 [-5·50 to -3·46]) individually. Upon study termination, 58% of spironolactone treated patients achieved blood pressure control versus about 42% of doxazosin, and 43% of bisoprolol patients. There was an inverse and linear relationship between renin and blood pressure response to spironolactone, a fi nding not seen with bisoprolol or doxazosin. Serious adverse event rates, including hyperkalaemia, were less than 3% in each group.
Williams and colleagues 9 provide the strongest support yet for the antihypertensive effi cacy of spironolactone in cases of resistant hypertension. The mandatory use of pretrial diuretics and the assessment of clinic and home blood pressures allow the authors to exclude patients with so-called white coat hypertension. The implementation of renin profi ling, previously shown to predict responsiveness to diuretics, 10 was an accurate predictor of spironolactone response.
Despite these promising results, there are limitations to extrapolation of the results of PATHWAY-2 to the general population. The study design does not exclude a carry-over eff ect, because there were no interval washout periods between drugs, but the authors noted almost identical diff erences between drugs when only the fi rst cycle treatments were compared in a parallel group fashion (appendix p 16). 9 In view of the duration of spironolactone activity, this extended eff ect would be advantageous to the comparator drugs; however, treatment with spironolactone yielded about a 6 mm Hg greater reduction in systolic blood pressure compared with bisoprolol or doxazosin at 12 weeks. Additionally, there was a 4 mm Hg diff erence favouring spironolactone in the primary comparisons of average systolic blood pressure on low and high doses. Would similar results be achieved in an African-American or Afro-Caribbean cohort? Can these results be applied to patients with advanced kidney disease at risk for hyperkalaemia? Would people with much lower sodium intake than those participating in this study, in whom 24-h urine sodium was about 137 mmol/L (8 g), still require addition Catheter-related bloodstream infections were once viewed as an inescapable consequence of prov iding care to critically ill patients. It was not until the beginning of the 21st century that a conceptual model identifi ed both technical and socioadaptive strategies to prevent this outcome.
1 Key among technical factors were processes such as skin disinfection with chlorhexidine and use of large drapes at the time of insertion to prevent catheter contamination. Conversely, socioadaptive factors were focused on behavioural aspects such as adhering to proper hand hygiene, nurse-led halts if parts of sterile insertion were not followed, and targeting of unit-specifi c culture to increase compliance. Although closely intertwined, combining technical and socioadaptive factors within a bundle of best practices has substantially reduced catheter-related bloodstream infections in the past decade.
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But which elements of this bundle are most responsible for reducing catheter infections? This question is not merely a point of academic debate, but one that has important clinical and policy ramifi cations. For example, empowering nurses to stop physicians if hand hygiene before catheter insertion is not performed or specifi c sterile technique is not followed requires changes in social norms and organisational culture. Such initiatives are diffi cult and might distract from more effi cient preventive measures if not eff ective. Alternatively, if a technical factor such as chlorhexidine is most responsible for reductions in bloodstream infection, then implementation of a chlorhexidine-only Vascular catheter infections: time to get technical of spironolactone? Additionally, would a longer acting thiazide diuretic such as chlorthalidone or indapamide reduce the need for spironolactone? Lastly, the average weight of participants in Williams and colleagues' cohort was around 94 kg, generally less than that in some areas of the world. Future studies need to address these issues.
PATHWAY-2 9 makes the addition of spironolactone to a three-drug regimen hard to resist in cases of resistant hypertension among overweight patients with stages 1 and 2 kidney disease. Newer aldosterone antagonists such as fi nerenone with less risk of hyperkalaemia 11 and potassium binders, such as patiromer, 12 will be available soon, to aid in reducing the risk of hyperkalaemia in the subset of resistant hypertensive patients with stage 3B or higher kidney disease. PATHWAY-2 provides strong evidence for an approach to conquer the problem of resistant hypertension in the general population.
